Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Urothelial Cancer 1Urinary Bladder Neoplasms 1Prostate Cancer Patients 1Prostate Cancer Metastatic 1Postoperative Cognitive Complications 1Pharmacokinetics of MDV3100 1Pain 1Lung Neoplasms 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

repaglinide 1carbon-11 acetate 1Warfarin 1Omeprazole 1Midazolam 1Interviews as Topic 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Patients × Midazolam × Genitourinary × Clear all
NCT04676035 2023-02-09

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡